CODX Share Price Performance
US$0.36
-0.58 (-61.44%)
88.0% undervalued intrinsic discount
US$3.00
Fair Value
Price US$0.36
AnalystConsensusTarget US$3.00
AnalystLowTarget US$1.00
AnalystHighTarget US$10.00
Fair ValueUS$3.00
Share Pricen/a
Co-Diagnostics, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
CODX Community Narratives
AN
Fair Value US$3 88.0% undervalued intrinsic discount
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
0users have liked this narrative
1users have commented on this narrative
6users have followed this narrative
AN
Fair Value US$1 63.9% undervalued intrinsic discount
Revenue Drops And Regulatory Delays Will Spark A Cautious Rebound
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$10 96.4% undervalued intrinsic discount
Decentralized Diagnostics Will Expand Global Infectious Disease Surveillance
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Key Takeaways Entry into high-need global markets and decentralized testing supports sustained growth, recurring revenue, and broader healthcare impact through advanced diagnostic solutions. Proprietary platforms and strategic partnerships drive customer retention, efficiency, and market penetration while mitigating financial risks during commercialization.Read more
0users have liked this narrative
1users have commented on this narrative
6users have followed this narrative
AN
US$3
88.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
399.22% p.a.
Profit Margin
31.73%
Future PE
4.43x
Price in 2028
US$2.6
Revenue Drops And Regulatory Delays Will Spark A Cautious Rebound
Key Takeaways High execution risk and regulatory uncertainty threaten the company's ability to turn innovation into timely commercial gains, while persistent losses pressure financial sustainability. Intense competition, pricing pressures, and regulatory compliance challenges may hamper expansion, reduce margins, and limit market penetration in both domestic and international markets.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$1
63.9% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
279.14% p.a.
Profit Margin
12.42%
Future PE
8.12x
Price in 2028
US$1.05
Decentralized Diagnostics Will Expand Global Infectious Disease Surveillance
Key Takeaways Rapid global market expansion, local partnerships, and broad clinical trial efforts could accelerate revenue growth and create significant first-mover advantages. Unique cloud-connected platforms and diversified product offerings enable recurring premium revenue streams, improved margins, and resilience beyond pandemic-driven demand.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$10
96.4% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
278.94% p.a.
Profit Margin
12.42%
Future PE
81.34x
Price in 2028
US$10.48
Trending Discussion
Recently Updated Narratives
AN
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Fair Value: US$3 88.0% undervalued intrinsic discount
6 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Revenue Drops And Regulatory Delays Will Spark A Cautious Rebound
Fair Value: US$1 63.9% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Decentralized Diagnostics Will Expand Global Infectious Disease Surveillance
Fair Value: US$10 96.4% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Co-Diagnostics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.53
- 34.03%
- -6,336.27%
- 0%
About CODX
- Founded
- 2013
- Employees
- 132
- CEO
- WebsiteView website
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
